ABCC1 and non-small cell lung carcinoma: Consequently, TFEB silenced cells were more resistant than parental cells to PT and paclitaxel (Fig. 4H), two drugs used in NSCLC treatment and whose poor efficacy has been related to ABCC1 expression [48, 49].